Co-Authors
This is a "connection" page, showing publications co-authored by Yufeng Yuan and Ye-Mao Liu.
Connection Strength
1.018
-
REPLY. Hepatology. 2021 01; 73(1):470-471.
Score: 0.229
-
Kidney Function Indicators Predict Adverse Outcomes of COVID-19. Med (N Y). 2021 Jan 15; 2(1):38-48.e2.
Score: 0.226
-
Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology. 2020 08; 72(2):389-398.
Score: 0.224
-
A risk score based on baseline risk factors for predicting mortality in COVID-19 patients. Curr Med Res Opin. 2021 06; 37(6):917-927.
Score: 0.059
-
The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. Cell Metab. 2021 02 02; 33(2):258-269.e3.
Score: 0.058
-
Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020 10 06; 32(4):537-547.e3.
Score: 0.056
-
Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. Hypertension. 2020 10; 76(4):1104-1112.
Score: 0.056
-
Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. Hypertension. 2020 08; 76(2):e15-e17.
Score: 0.055
-
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020 06 05; 126(12):1671-1681.
Score: 0.055